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 The ubiquitous promise of personalized medicine associated with devel-
opments in genetic research, including the fi eld known as breast cancer 
genetics, has long been grounded in an assumption that this knowledge 
will facilitate the movement towards individualized and targeted treat-
ment based on knowing a person’s genotype. Despite emerging possibili-
ties for using knowledge of the two well-known inherited susceptibly genes, 
BRCA 1 and 2, in the treatment of sporadic cancers (see Bourrett, Keating & 
Cambrosio, 2014), this promise has been limited for the most part to the 
possibility of providing a personalized risk susceptibility estimate based on 
genetic testing to detect mutations on these genes. The normalization of the 
 anticipatory habitus (Joseph, 2014) associated with predictive interventions 
related to new fi elds of clinical intervention such as breast cancer genetics 
is refl ected in the growing incorporation of genetic testing for breast cancer 
as a standard of care across diverse fi elds of public and private health care, 
particularly in North America and Europe (see Gibbon et al., 2014). The 
announcement in 2013 by actress Angelina Jolie that she had undergone a 
prophylactic mastectomy following a positive result for a mutation on the 
BRCA genes provides a striking and very public example of this rationality 
in action, which as this chapter will illustrate, continues to have repercus-
sions in many diverse cultural contexts, indirectly and directly informing the 
expansion of predictive interventions for cancer.  1  
 The terrain on which genetics operates means that the promise of person-
alized medicine now coexists alongside an emerging fi eld of public health 
genomics (Bauer, 2013; Brand, Brand, & in den Bäumen, 2008; Taussig & 
Gibbon, 2013). This is changing the boundaries of how and where genetic 
knowledge is being made relevant to health care as well as the parameters 
of what is described as a preventative approach to cancer. Genomic research 
is now directly tied to large-scale epidemiological studies for communicable 
as well as noncommunicable diseases. At the same time, newer and faster 
sequencing techniques and technologies, which enable thousands of muta-
tions to be rapidly identifi ed, are informing and propelling novel terrains 
of genetic and epigenetic research in relation to cancer and other diseases. 
Questions of human biological variation and population differences have 
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also reemerged in recent years as central to, if problematic and evolving 
dimensions of, public health genomics. Some suggest that the turn to public 
health is about reenergizing a fi eld of science that has failed to live up to 
expectations (Whitmarsh, 2013), helping to extend its importance and rel-
evance (Lindee, 2013). However, as Karen Sue Taussig and I note elsewhere, 
also of signifi cance is the “social action set in motion by researchers seek-
ing to translate genomic knowledge and technologies into public health” 
(Taussig & Gibbon, 2013, p. 3). 
 Social science research has begun to examine the way that a range of 
high-end medical technologies are now being unevenly translated across 
diverse terrains of global health care delivery, such that these often coexist 
and are made available to patients against a backdrop of precarious public 
health care or a lack of basic health resources (Bharadwaj & Glasner, 2009; 
Biehl & Petryna, 2013). In such cases we see how hopes for and investments 
in medical technologies are being invigorated, even in arenas where there is 
a ubiquitous scarcity of other health care resources. 
 One striking example of the expanded terrain of specifi cally genomic 
health care is evident in the incorporation of some aspects of breast cancer 
genetics into public health in countries such as Cuba, as I have explored in 
previous research (Gibbon, 2009, 2013a). Nevertheless it is important to 
note the selective and partial nature of these developments, which often take 
place alongside a discomfort about and recognition of the diffi culties asso-
ciated with translating the potential of genomic interventions into health 
care, particularly in terms of the promise of personalized medicine. What 
has been described as the “absent presence” of predictive genetic interven-
tions associated with an increased risk of breast cancer has also been noted 
by others in contexts such as India and Italy (Gordon, 2014; Macdonald 
2014; see also Kampriani’s work on Greece, 2009). In these domains, con-
cerns about the lack of basic clinical care for those with breast cancer and/
or the irrelevancy of predictive interventions, in the light of often scarce 
resources, directly and indirectly informs diverse responses to and engage-
ments with novel fi elds of health care intervention and technology. Despite 
these concerns, high-profi le technologies such as breast cancer genetics have 
now become part of transnational fi elds of research carried out in relation 
to diverse and highly variable public health care provision (Gibbon et al., 
2014). Such developments refl ect and also fuel the extremely fl uid relation-
ship between research and care that has, as Hallowell and colleagues (2010) 
note, been a particular feature of cancer genetics. 
 Anthropologists who explore the now broad global terrain of clinical 
trial research have consistently demonstrated how participation in research 
is a process that can constitute subjectivity and citizenship in ways that both 
include and exclude (Biehl, 2007; Nguyen, 2010; Petryna, 2009; Rajan, 
2005). Although inequities characterize these social relations, participation 
in clinical trial research can also become a strategy for obtaining medical 
care (Biehl, 2007; Fisher, 2009). In this way ancillary care has the potential 
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to become an expression of the ethical variability (Petryna, 2009) of the 
global outsourcing of clinical trials. Marissa Mika (2013), exploring the 
social repercussions of global clinical trial research on the practice of oncol-
ogy in Uganda, also points to the way that such research can become a 
resource for wider communities of health care professionals and practice. 
 This chapter examines how, in the context of Brazilian cancer genetics, 
research becomes caught up with constituting clinical need, rights and care. 
It explores the uneven and disjunctured ways that research on cancer genetics 
in Brazil is framed and reproduced as a resource. I show how patients and 
practitioners engage with and are constituted by predictive and risk-reducing 
interventions resulting in diverse forms of patient/professional activism. My 
goal is to shed light on the sociocultural dynamics and tensions by which 
prevention, public health and clinical need are being calibrated at the meet-
ing points  and interstices between global cancer genetic research, the limits 
of public health as well as its pursuit as a national imperative and the rising 
incidence of cancer in Brazil. In this way I illustrate how global research 
trajectories, propelled in part through an emphasis on genomics as a form of 
preventative public health, inform local clinical practice at the same time that 
inequities in the Brazilian health care system comprise and propel the pursuit 
of cancer genetics as both a right to health care and a resource for research. 
 The data discussed and presented here draw from 18 months of ethno-
graphic research carried out in three urban locales in the southern region of 
Brazil, including periods of participant observation in cancer genetic clin-
ics, interviews and questionnaires with patients and their families, and also 
interviews with medical practitioners and scientists in cancer genetic clinics 
linked to public and mixed private/public hospitals including cancer genetics 
specialists, oncologists, mastologists and biologists.  2  
 ONCOGENÉTICA IN BRAZIL: BETWEEN UNMET NEED, 
RESEARCH AND PUBLIC HEALTH 
 The appearance of  oncogenética or cancer genetics in Brazil is a recent 
development emerging in the last eight years partly in response to the high 
national incidence of cancer. Brazil has over 50,000 newly diagnosed cases 
of breast cancer each year, a rate that is comparable to the US population. 
According to the  Instituto Nacional de Câncer (INCA, 2014) linked to the 
Brazilian Ministry of Health, based on data gathered from population reg-
istries, there are also regional differences in the incidence of cancer with the 
highest rates of breast cancer reported for the southern states of Brazil (see 
also Lee et al., 2012, p. e96). Whereas some northern states and cities are 
reported to have an incidence of breast cancer that is 10 times lower than 
some of these southern regions, the northeast and north have signifi cantly 
higher rates of incidence and mortality from cervical cancer (Azevedo & 
Silva, 2010) . 
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 There have been recent efforts to address rising rates of breast cancer in 
Brazil, including legislation in 2009 by the Brazilian Ministry of Health to 
recommended mammography screening every 2 years for all women between 
50 and 69 (and at 35 years of age for those with a family history). However, 
limited data suggest not only that the infrastructure for providing mammo-
grams are starkly different between northern and southern regions, but over-
all national mammography screening rates remaining substantially lower 
than WHO recommendations to screen over 70% of the population, with 
doctors in Brazil reporting that 80% of breast cancer cases are identifi ed and 
brought to their attention by patients (Lee et al., 2012; p. e96). Moreover 
a recent Brazilian study examining breast cancer outcomes across different 
regions in Brazil found that women who received public health care had 
more advanced disease, less access to modern health care and treatments, and 
lower survival than those treated at private institutions (Simon, et al., 2009). 
 These disparities in access to and provision of breast cancer services 
refl ect the broader complexities of public health provision in Brazil. The 
constitutional right to health emerged in post-dictatorship Brazil, informed 
by the efforts of various social movements to democratize health care. Nev-
ertheless, the changes that this brought about have been contradictory and 
uneven (Biehl, 2005; Edmonds, 2010; Sanabria, 2010). About 75% of the 
population has access to health care only through the public health care 
system or SUS (Sistema Único de Saúde), with the rest of the population 
making use of health plans and insurances.  3  At the same time, the avail-
ability and relative affordability of health insurance for the middle class has 
meant that many choose not to use public services, seeing them as offering 
substandard care, a process that Faveret and Oliveira (1990) describe as 
“excluding universalism.” Nevertheless, there is, as Sanabria (2010) in her 
examination of hormones and public health in Brazil points out, a great deal 
of movement of doctors, patients and protocols between private and public 
health care domains. 
 Some of that movement is refl ected in the context of cancer genetics 
in Brazil, which is nevertheless emerging mainly in the relatively wealthy 
southern regions of the country. With genetic services not currently covered 
by the public health care system, cancer genetics operates in something of an 
interstitial space between research and public health. That is, it is practiced 
at the meeting point and gaps between the research activities of individual 
Brazilian researchers or their teams involved in collaborations with other 
scientists in the United States, France and Portugal, and precarious and lim-
ited public health interventions including screening or monitoring interven-
tions such as mammography.  4  In this way, Brazilian cancer genetic services, 
situated by those who work in the fi eld in Brazil as a  preventative approach 
in a context of scarcity and limited resources, is mobilized and enacted in 
part through globalized clinical and transnational research collaborations. 
 The fi rst part of this chapter explores some of these dynamics from the 
perspective of health care practitioners and scientists. It shows how the 
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 activism of these individuals within cancer genetics must be understood and 
rendered explicit as it serves to constitute clinical need, situate and extend 
research priorities in relation to transnational research collaborations, and 
provide care as part of a neglected preventative approach in a context of 
limited resources. The second part of this chapter examines the experience 
of patients who participate in, and in some cases pursue the  right to what is 
perceived as preventative health.  5  
 ACTIVIST PRACTITIONERS: UNKNOWN RISK AND 
THE POLITICS OF PREVENTION 
 There has been growing attention to population difference in genetic research 
tied in part to the emergence of public health genomics. That is, as testing 
widens across a global terrain it reveals gaps in medical knowledge based on 
databases of known mutations in previously identifi ed risk populations in 
national contexts such as the United States, Canada and Europe. This fuels 
and informs a focus on identifying variation on the  spectrum of currently 
unknown mutations that might be implicated across different national con-
texts as part of the pursuit of public health genomics. For some this has been 
described as linked to an emerging trajectory associated with the pharmaceu-
tical industry of niche marketing (Lee 2005). Others point to the tensions this 
has generated in the way that the so-called underserved needs of neglected 
groups and populations are being reformulated in terms of both a resource 
and right to research and care. As Rayna Rapp (2013) points out “multiple 
publics have become part of exquisitely stratifi ed research populations that 
now serve as potential global resources and market benefi ciaries” (p. 574). 
 As I have explored elsewhere, moves to expand cancer genetics in con-
texts such as Brazil are emerging alongside and in tension with transna-
tional research agendas linked to population difference (Gibbon, 2013b; 
Mozersky & Gibbon, 2014). Within Brazil, an emphasis on the  unknown 
contribution of genetic risk in understanding the rising rates of cancer in the 
country reveals the limits of international standardized risk models and fuels 
the pursuit and activism of practitioners caught up in Brazilian cancer genet-
ics framed in terms of fi nding more appropriate local estimations of genetic 
risk for the Brazilian population. In practice, however, efforts to identify the 
particular genetic aspects of the Brazilian population that may be relevant 
in terms of genetic ancestry and establish the relevance (or irrelevance) of 
certain mutations linked to an increased risk of cancer can involve both the 
incorporation and simultaneous rejection of categories of race and ethnicity 
(Mozersky & Gibbon, 2014; see also Santos, Silva & Gibbon 2014). 
 Nevertheless, putting into practice Brazilian cancer genetics and consti-
tuting it as clinical need are closely tied not only to efforts by practitioners 
to attend to as yet unknown national parameters of population difference, 
but also to a moral economy that conceives of cancer genetics as prevention. 
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Such moves parallel broader shifts in the way that a focus on population dif-
ference, particularly in the fi eld of BRCA genetics, has been constituted as a 
movement towards prevention.  6  
 This was evident in the way one young trainee cancer genetic practitioner 
in Sao Paulo passionately described the necessity of cancer genetics in Brazil. 
 Why do we need this? Because we see the importance when you inter-
view a family that has multiple cases of cancer in the family and under-
stand the desperation of those families when they ask, “what should 
I look for?” “What should I do?” “Who’s going to help me get early 
screening for my daughter, for my sister?” Because of this, it’s vital that 
Brazil has in its public health system, cancer genetic clinics to try and 
help these families, and to have in our Brazilian statistics understanding 
of the genetic diseases that we are transmitting to our families . . . the 
populations going to grow and develop and transmit these mutations, 
so we have to know how to deal with this in the long term. 
 Here we see how an emphasis on attending to underserved populations 
who do not have access to basic health services is entwined with the per-
ceived need to understand and gain knowledge about Brazilian statistics 
related to genetic risk as part of an emerging preventative approach framed 
in terms of having access to early screening and care for those at risk in the 
family. Such sentiments were refl ected in the comments of another practitio-
ner who described cancer genetics in terms of “protection for the family,” 
stating that such individuals could have “a higher risk of having a tumor.” 
Likewise, she added “I really think that cancer genetics is prevention.” 
 For many of those who worked in the cancer genetics fi eld there was a 
great deal of frustration associated with trying to ensure those who had been 
identifi ed as being at risk were offered appropriate  preventative interven-
tions. In the mixed private/public hospital where I worked in Sao Paulo, 
I frequently witnessed the convoluted tasks that nurses and geneticists 
engaged in trying to ensure all those potentially at risk in the family were 
able to obtain extra screening once a family member had been identifi ed 
as carrying a mutation. When one person had a  convenio or private health 
insurance that covered certain kinds of interventions such as extra screening 
but others in the family did not, doctors and nurses skillfully maneuvered 
between the limits of the public health system, research protocols, hospital 
provision and the rules and regulations of different health insurers to make 
every effort to ensure that as many family members as possible were able to 
obtain screening. 
 The logic of cancer genetics for health for many of these professionals 
was evident. They emphasized not only the moral economy of prevention in 
terms of care for the family but the cost–benefi ts of cancer genetics to iden-
tify those at risk compared with the cost of treating those who developed 
breast cancer. This was how one geneticist in Porto Alegre put it, 
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 If you have a family who [has] every likelihood of carrying a BRCA1 
and BRCA2 gene, it’s much simpler to test and know who has the muta-
tion and who doesn’t, rather than to screen everyone. If you imagine 
that 50% have the mutation and 50% don’t, for at least half of those 
you don’t have to do anything and that’s a saving. The problem is the 
issue of compromising. I’m seeing a family today that needs the test that 
I can offer but it’s very expensive;  SUS doesn’t offer this. But what hap-
pens if I leave it there and not worry about this and pretend there isn’t 
a problem? . . . I just can’t for another ten years keep doing research 
to offer testing . . . with care being something peripheral that [is] just 
tacked on the side. 
 In this instance it is not only the logic of cancer genetics as public health 
and prevention that is articulated, but also a frustration engendered by 
attempting to manage a clinical service that is ultimately dependent on 
research funding. Nevertheless, it is important to note that the idea of cre-
ating cancer genetic services within public health as part of a preventative 
approach was not supported by all health professionals I met in Brazil. In 
one public health hospital where I discussed this possibility with those who 
worked in the broader fi eld of mastology (a health care specialty focused 
on breast health), there was considerable doubt about the value of cancer 
genetics in a  SUS hospital. One of the mastologists began our interview by 
pointing to the very same challenge that the Brazilian cancer geneticists had 
identifi ed, the lack of knowledge relating to the relevance of current knowl-
edge about genetic risk for the Brazilian population. As he said, “there isn’t 
a study of the Brazilian population on wide scale as yet that says what size 
of the Brazilian population is affected whether its 5, 10 or 15% genetic 
risk—that data doesn’t exist.” 
 But he also by contrast drew stark attention to the costs associated with 
such interventions: 
 It [genetic testing] is just not very common here [referring to the public 
hospital where he worked] because this involves costs. A hospital like 
this that looks after essentially a socially insecure population doesn’t 
provide this because of the costs involved in these kind of tests, if they 
were available and used more freely. 
 Relating this situation back to the lack of knowledge about cancer risk 
in Brazil he continued: 
 If you don’t have the criteria, you start to waste money and here we 
don’t have money to waste . . . perhaps there are other priorities that 
should be addressed and would help lessen the impact of a particular 
disease . . . we have to select where we are going to invest our money, 
resources and materials . . . so I think we still don’t have a justification 
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for having a big national program that would involve lots of human 
resources. The test isn’t certain even, it just says whether you have a 
risk or chance of having it or not so perhaps sometimes we are creating 
problems that we can’t resolve and for which we can’t really offer a very 
good solution. 
 In this case, the moral framing of cancer genetics as prevention is con-
tested and brought into question in relation to the unknown component 
of genetic risk in Brazil and the cost of such interventions in resource-poor 
contexts. For some medical professionals (in this case those working in a 
related specialty that in fact prides it itself on adopting a  holistic approach to 
breast health and the treatment of breast cancer), cancer genetics sits outside 
the realm of public health care and prevention due to both cost, unknown 
relevance and the uncertainty that it intervenes upon and also generates. 
This points to the limits of practitioner activism highlighting greater varia-
tion and diversity in the affective framing of cancer genetics as prevention 
across diverse domains of breast cancer care within spheres of public health 
care provision in Brazil. 
 ACTIVIST PRACTITIONERS AND  ROAD TRIPS : THE 
PURSUIT OF RESEARCH AND PREVENTION 
 Events that provided some informative ethnographic insight on how the 
 activism of cancer genetic practitioners facilitated the productive conjunc-
tion between participating in global research agendas and pursuing cancer 
genetics as public health were what were described as  road trips made by 
some of the researchers I met. These were often undertaken by teams of the 
local and international cancer genetic researchers and health professionals 
to the interior and rural parts of the southern states of the country, as they 
engaged in efforts to seek out and identify individuals and families affected 
by hereditary cancer syndromes. 
 I accompanied one group of health professionals to the interior of the 
state of Sao Paulo to meet with an extended family who had experienced 
many cases of cancer, and recount some of that event in the following excerpt 
from fi eldnotes: 
 We arrived early one morning in a rural region at the family home of one 
young female patient in her mid-20s who had been treated some years earlier 
for cancer at the hospital in Sao Paulo. Sonja was a student in Sao Paulo 
but had a large family in the interior of the state, which she had returned to 
on an overnight bus to meet us early in the morning at her aunt’s house. It 
was in this moment, noticing the slight anxiety of Sonja as she watched and 
greeted family members as they arrived, that it became clear how she had 
been a central fi gure in the gathering of her relatives to meet the cancer genet-
ics team as aunts, uncles and young relatives arrived at the entrance to the 
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house. Giving an impromptu talk to the families the practitioner described 
the visit in terms “a chance to participate in research” and “a way of pre-
venting cancer in the future” and also a “an opportunity to see who is at risk 
so that they can be offered treatment in Sao Paulo.” She added that it was 
not, of course, obligatory to participate in the research, which was totally 
voluntary. Later I was told by one member of the team that it was unlikely 
that many of the family had convenios or private health insurance and living 
in a rural part of the state were, as a result, without easy access to health 
care services such as routine basic health care screening. While not explicitly 
stating that being involved in the research was a means to secure routine 
preventative screening from the hospital in Sao Paulo it seemed from these 
remarks that, from the point of view of the health professionals involved, 
this was perceived as an indirect benefi t of participating in research. 
 Sitting in the make-shift space for collecting blood samples for research, 
which had been set up in one of rooms alongside the nurse, it was obvious 
that many of the preoccupations of those who agreed to donate blood for 
research were related to more immediate health care problems rather than 
the future risk of cancer per se. One elderly relative had a lot of pain in her 
neck and she asked if she should see someone in the hospital in Sao Paulo. 
The response of the nurse in this instance was not to be concerned for the 
moment about these health problems as the fi rst thing to do was to fi nd out 
if they were carriers of the mutation that Sonja had, pointing out that if 
they also carried the same mutation then they would be able to have access 
to more investigations. It seemed then from what the nurse was saying that 
a preventative approach was therefore predicated on the necessity through 
research of identifying those at highest risk. 
 The steady fl ow of relatives willing to donate blood and participate in 
the research generated a good deal of energy and enthusiasm among the 
researchers. In the car on our return there was much excitement that they 
had been able to collect so many samples in one visit and discussion about 
whether this would enable to them to map further clusters of cancer in the 
region as they had already done with a number of other families. But there 
was also some discussion of the social context of the family and, given the 
lack of access to health care through private health insurance, the extent to 
which other family members might through research protocols be encom-
passed by the care provided under the aegis of the cancer genetic research 
protocols at the hospital. There was in fact heightened awareness that this 
was essentially precarious, predicated on continuous funding from interna-
tional collaborations and the ongoing willingness of the hospital to include 
at risk family members, not just those with cancer, in the hospital’s protocols 
for screening interventions. 
 The events such as the road trips say much about activism on the part of 
these professionals. I would argue that these are not entirely explainable in 
terms of a perspective that views them as examples of the exploitation of 
vulnerable communities simply for the purpose of research collaborations 
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and publications. There are both moral and affective dimensions associated 
with practitioners’ efforts to pursue cancer genetics as public health via col-
laborative transnational research. The seeking out families in this way was 
not then  only about furthering research ends, or simply identifying those at 
most risk, but was also about facilitating access to basic health services in 
efforts to meet what these practitioners perceived as the neglected broader 
goals of a preventative approach to health care. Nevertheless, as the road 
trips make clear, the role of patients in facilitating and mobilizing cancer 
genetic research as prevention is also central. In the fi nal part of the chapter 
I turn more directly to examine the experience and perception of patients 
engaged with cancer genetic research in Brazil. 
 A LONGING FOR CARE AND THE RIGHT TO HEALTH 
 Only a handful of the vast majority of patients I met while carrying out 
research in three urban centers was able to muster the $2–3,000 necessary 
to pay for a genetic test. Most had arrived in the cancer genetic clinics fol-
lowing referral by a family member who had been treated at the hospital for 
cancer and were for the most part  SUS patients.  7  As a result, their own and 
their family members’ eligibility for testing was, for the most part, tied to a 
specifi c study protocol. Many were waiting for test results but as part of a 
program of research were also in receipt of other basic screening and health 
monitoring services. For many of these individuals simply being within the 
parameters of the hospital’s care through participation in research was per-
ceived as prevention. As one middle-aged female cancer patient who had 
had breast cancer but was now part of a study protocol relating to research 
on the two BRCA genes put it, “this works as prevention . . . if there was 
more of this type of research perhaps persons wouldn’t arrive with cancer as 
it was in my case.” Referring to her children she added: 
 My daughters will now have much more care, they will be examined 
much earlier, perhaps have preventative screening much earlier and 
perhaps not come having developed cancer—this is a procedure ( uma 
regra ) that would be useful for everyone. 
 For others, being involved in this type of program went beyond preven-
tion to being actively part of the search for a cure. As the following com-
ments from a female patient in Sao Paulo suggest, this perception resulted 
in an eagerness and willingness to be part of such study protocols, where 
being a  guinea pig, far from being something negative, was actively sought 
out and valued. As she said: 
 I think that the future cure for cancer is in genetic research. Look take 
my cancer cells and make a vaccine! I think this will happen. I think 
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that genetics isn’t just about prevention but a question of cure as well. 
Whenever they have this kind of research at the hospital I always say 
yes, I would really like to be a guinea pig in the cure for cancer. 
 Although these sentiments were shared by a number of patients, the 
majority of those I met felt a sense of relief that by participating in the 
research provided by the hospital they had access to regular screening and 
specialist health care. As we saw in the case of the road trip described previ-
ously, patients recruited into research perceived this as a means of accessing 
basic health care. This was also the case for Maria, a cleaner in her 40s who 
worked in Porto Alegre, as she talked about what it meant to her (and the 
diffi culties she had also experienced) in her efforts to be under the aegis of 
the specialist hospitals’ cancer genetic services: 
 When you manage to get a consultation with the doctor you’re relieved 
but to arrive here you have to go through tremendous bureaucracy, 
queue for hours. In other hospitals you have to wait nearly one year to 
do a mammogram or 8 months for meeting with the doctor—the prob-
lem is getting in here [referring to the hospital associated with the cancer 
genetic research]. Once you arrive here everything’s a blessing ( tudo e 
a abencoada )—the problem is in getting here. [Now] I feel protected, I 
have screening and if I have a problem I know that I can have chemo-
therapy or surgery . . . I don’t have the words to describe how grateful 
I am to you for all that you are doing here.  8  
 The ways patients describe their experiences of participation in research 
reveal then a particular scale of investments that constitute an expanded space 
of possibilities for cancer genetics in Brazil. For these individuals this includes 
hopes for prevention or cure and participation in research becomes a strategic 
means of accessing often precarious or hard-to-get basic care and resources. 
 In an examination of the newly emerging fi eld of public health genomics 
in Barbados, Ian Whitmarsh (2013) suggests that as genetic diagnosis, moni-
toring and surveillance are increasingly conceived as forms of preventative 
public health and a social good, there is an ethical imperative for individuals 
to fashion and discipline themselves into what he describes as new subjects 
of “biomedical compliance.” Although some elements of these forms of sub-
jectivity may be apparent in the narratives recounted in this paper there is, 
as Biehl and Petryna (2013, pp. 14–15) point out, a need to guard against 
a “uniform and unilateral diagnosis” to examine the “granular ways” in 
which supposedly neoliberal principles, tied in this instance to proactive 
patienthood required by genetic screening interventions, become “part and 
parcel of public health landscapes and social relations in resource poor con-
texts.” As Petryna (2013) has noted elsewhere, there are often novel pos-
sibilities for the crafting of rights and responsibilities in such contexts that 
must be attended to and accounted for. 
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 One very powerful illustration of this is evident in an emerging phenom-
enon in Brazil that is transforming the parameters and pathways by which 
patients are accessing health care services, linked to a process described as 
the judicialization of health and the phenomenon of patient litigants. In 
conclusion, I show how this is becoming evident within and developing as a 
direct consequence of the interstitial space in which Brazilian cancer genetics 
operates. Such phenomenon serve to further illuminate the diverse vectors 
through which an  anticipatory habitus embedded in the preventative prom-
ise of cancer genetics is becoming part of new and novel claims and rights 
to health in Brazil. 
 As noted in recent studies by Joao Biehl and Adriana Petryna (2011, 
2013), thousands of Brazilian patients across different social and economic 
classes are effectively suing the government for the right to health care 
resources such as medications, but also now other treatments, examinations 
and tests, predicated on a constitutional commitment in Brazil to provide 
health care for all. Patients litigants, who appear to comprise a broad sec-
tion of social classes, are not simply “waiting for the high cost of medicine 
technologies to trickle down” but are instead “using public assistance and 
the levers of a responsive jury to gain full access now” (Biehl & Petryna, 
2011, p. 363). Whereas the fi rst such successful cases of judicialization have 
occurred in the context of participation in clinical trial research for medica-
tion related to mainly rare genetic conditions, increasingly patients are pur-
suing and successfully obtaining the right to health care resources outside 
these parameters by accessing mostly free legal services. As I illustrate next, 
this now includes the right to have a predictive genetic test for breast cancer. 
 In October 2013, I returned to Brazil as part of a research visit to the 
southern part of the country. Within minutes of meeting friends and col-
leagues working in one of the cancer genetic clinics there were numerous 
comments about Angelina Jolie’s announcement made six months previ-
ously. From what they said it was clear that this had generated a lot of 
polemical discussion in the Brazilian media, as well as signifi cantly raising 
the profi le of cancer genetics in the country. “Thank goodness for Angelina 
Jolie,” said one genetic practitioner casually as she talked to me of how the 
numbers at the cancer genetic clinic in a mixed public/private hospital in 
Sao Paulo had grown exponentially since the highly public statement by the 
actress and the ensuing media focus. While also pointing out she had as a 
result been approached by numerous television, radio and media outlets to 
comment on the announcement, she told me how referrals to the clinic and 
interest from publics had increased threefold in the ensuing six months. In 
another public hospital in Rio, it was notable while sitting in on a couple 
of consultations with practitioners whom I had gone to meet that Jolie’s 
name was mentioned again, this time in the process of explaining the risk 
of having a BRCA mutation to a patient. The nurse genetic counselor used 
reference to Jolie’s announcement as a way it seemed of almost normalizing 
the procedures that she was offering the patient; in this case, the possibility 
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of having a genetic test linked to a particular research protocol. But it was 
at another public hospital in Porto Alegre where another dimension of these 
developments came to light. 
 The genetic practitioner there told me how in the last few months at least 
one or two of the 30 or so new patients without private health insurance 
seen each week had come armed with letters from lawyers saying that they 
were going to “ entra na justicia” (go to the courts) to demand the govern-
ment pay for them to have a genetic test, saying that they have a “right” ( um 
direto ) to the test that Angelina Jolie had. Although not totally supportive 
of judicialization as the best means by which patients should have access to 
health care (or equally that the action of celebrities should have this effect 
rather than reasoned science and research), the doctor I met acknowledged 
that the phenomenon of patient litigants in the context of cancer genetics 
was changing the health care landscape in which they were working. More-
over, she thought this was likely to put increasing pressure on the state to 
incorporate cancer genetics as part of the public provision of health care, 
a goal that was much sought after by many of those who worked in this 
emerging fi eld of cancer care in Brazil. 
 The full consequences of the expansion of judicialization processes to 
include procedures such as predictive genetic testing is still unfolding in Bra-
zil with cases being examined at federal and state level in what is normally 
a fairly drawn out process that can take many years. Nevertheless, the very 
fact that this phenomenon is happening now in Brazil further illustrates the 
complexities of the interstitial spaces in which Brazilian cancer genetics is 
coming into being and the way that an  anticipatory habitus is becoming 
bound to a discourse of rights, not in this case to access treatment, but to 
pursue genetic testing as part of what is seen as preventative approach. 
 CONCLUSION 
 In this chapter I have explored the tensions and dynamics surrounding the 
way one domain of high-technology medicine associated with a transform-
ing terrain of public health genomics is being mobilized and constituted as 
a social good, linked in part to a discourse of cancer prevention. In Bra-
zil this is emerging in the not-easily-disaggregated meeting points between 
transnational research and precarious public health care provision in efforts 
to address and ameliorate the effects of rapidly rising cancer incidence and 
mortality. As Whitmarsh (2013) points out, while the pursuit of genetic 
research in resource-poor settings might be seen simply as an effort to simply 
“join in on cutting edge biomedicine,” it also informs and transforms what 
counts as public health. 
 In Brazilian cancer genetics, patients participate in research in hopes of 
accessing basic health care services and what is perceived as the right to 
pursue prevention. At the same time, the activism of health professionals is 
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central to collaborations in transnational research on the unknown genetic 
risks of breast cancer for the Brazilian population and to addressing under-
served health care needs as part of a neglected preventative approach to 
health care. Yet this moral and affective framing of cancer genetics as pre-
vention is not shared by all of those who work in related fi elds of health 
care, pointing to the limits of such activism and to differing perceptions 
about how public health and prevention should be pursued. Nonetheless, 
the anticipatory habitus constituted by fi elds of knowledge such as breast 
cancer genetics in Brazil seems to have found new expression in the wake of 
the activities of one global celebrity, which in conjunction with an expand-
ing arena of judicialization in Brazil may potentially inform public health in 
as yet unknown ways. 
 Transnational research, and particularly clinical trials research, is embed-
ded in complex structures of inequality and power that can work to exploit. 
At the same time, the particular institutional confi guration of research and 
clinical intervention outlined in this chapter related to cancer genetic research 
in Brazil is also the context through which patients seek and often obtain 
basic health care in pursuit of prevention. It is similarly a nexus through 
which national research initiatives are nurtured and developed, previously 
nonexisting clinical specialties and professional identities are forged, and the 
means through which collective demands for wider public health care provi-
sion can be made to foreground an ethic of prevention. 
 As others have noted, the boundary between research and clinical care 
is often thin in the context of genetic research where research participation 
is often regarded as having diagnostic consequences or therapeutic bene-
fi ts (Hallowell et al., 2010). This is particularly so in the context of cancer 
genetics where many hybrid activities take place given its inherently trans-
lational dimensions (Hallowell, 2009). Highlighting how the moral fram-
ing of research and clinical care are often closely and complexly entwined, 
Wadman and Hoeyer (2014) point out that it is important to not see this 
necessarily as a dilemma or obstacle but as a way to understand how both 
can thrive on coexistence and the way that knowledge, work ethics and 
emotions emerge in tandem (p. 7; see also Timmermans, 2010). While the 
enmeshed boundaries between research and care in transnational research 
generate different questions and challenges, given inequities and disparities 
in resources, it is important to see how and in what ways for different groups 
and individuals in specifi c local contexts research is constituted as a resource 
and resourcefully acted upon. 
 As the changing techniques, including the rapidly diminishing price of 
genomic screening for diseases such as cancer, are unevenly incorporated 
across and within developed and also increasingly emerging and developing 
country contexts, it will be important to monitor in comparative cultural 
arenas the ways that clinical need, prevention and rights to health become 
part of diverse efforts to shape and reshape the making of public health 
genomics. 
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 NOTES 
 1. This development has generated much discussion across a range of public and 
social media and there is increasing evidence that the so-called “Angelina Jolie 
effect” has led to a marked increase in enquiries and referrals to cancer genetic 
clinics in the UK and elsewhere (Joseph, 2014; Retassie, 2013). 
 2. This work was funded by the Wellcome Trust (grant WT084128MA) as part 
of a project titled “Admixture, Ancestry and Breast Cancer in Brazil: An 
Ethnographic Investigation of Population Genetics, Disease Risk and Iden-
tity.” Research included participant observation in cancer genetic clinics over 
a period of 18 months in three different urban centers of Brazil, interviews 
with patients and family members attending cancer genetic clinics (over 100 
in total), and interviews with practitioners and scientists working within or 
alongside cancer genetic specialists (over 40 in total). Participating patients 
were attending cancer genetic clinics and were either undergoing, had received, 
or were awaiting the result of a genetic test on BRCA1 or BRCA 2 or R337h 
(a mutation thought to have a high frequency in the southern part of Brazil). 
Whereas the majority were women there were a number of men also recruited 
in the study, all were over 18. 
 3. See “Brazil’s March towards Universal Coverage” in Bulletin of WHO, Vol-
ume 88, pp. 641–716. 
 4. In 2012 private insurance companies in Brazil agreed to pay for genetic testing 
for those with insurance schemes or  convenios . During the time of most of my 
research however this was not the case, although a number of patients were 
advised to approach their health insurance provider by cancer geneticists in the 
hope of being able to secure a test. 
 5. The activism of health care practitioners is also an aspect that I’ve explored in 
the context of research on cancer genetics in Cuba (Gibbon 2013a). 
 6. This is evident in the growing calls in Canada and Israel for programs of 
population-wide screening of all Ashkenazi Jewish women and increasing 
interest in targeted screening interventions for certain populations, such as 
African American women with breast cancer diagnosed at a young age, with 
family history or with triple negative tumors (see for instance Churpek et al., 
2013 and also Joseph, 2014). 
 7. Approximately 15% of the over 100 families and individuals who were inter-
viewed had  convenios or private health insurance and under 5% privately paid 
for genetic testing. 
 8. This patient quote also appears in Gibbon (2013b). 
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